Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001884220 | SCV002153479 | pathogenic | not provided | 2021-12-02 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Trp153*) in the ALPL gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ALPL are known to be pathogenic (PMID: 3174660, 10679946, 19500388). This variant is present in population databases (rs761836226, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with ALPL-related conditions. For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV003464207 | SCV004193028 | likely pathogenic | Adult hypophosphatasia | 2023-05-10 | criteria provided, single submitter | clinical testing | |
Clinical Genetics Laboratory, |
RCV001884220 | SCV005199526 | likely pathogenic | not provided | 2022-07-13 | criteria provided, single submitter | clinical testing | |
Clinical Genetics and Genomics, |
RCV004765360 | SCV005375314 | pathogenic | Infantile hypophosphatasia | 2024-09-10 | criteria provided, single submitter | clinical testing | The p.(Trp153*) variant was seen in compound heterozygosity together with a missense variant (p.Asn124Asp) in a fetus with Hypophosphatasia. The variant is classified as pathogenic based upon ACMG critera PVS1, PM2 and PP5. |
Fulgent Genetics, |
RCV005016747 | SCV005642345 | likely pathogenic | Adult hypophosphatasia; Childhood hypophosphatasia; Infantile hypophosphatasia | 2024-06-13 | criteria provided, single submitter | clinical testing |